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Abstract
 
Reportedly, antiapoptotic Bcl-2 family proteins suppress apoptosis by binding to and inhibit-
ing members of the CED-4 family of caspase activators. To explore this question, we used
 
embryonic stem (ES) cells in which one (
 
2
 
/
 
1
 
) or both (
 
2
 
/
 
2
 
) copies of the gene encoding
apoptotic protease activating factor 1 (Apaf-1), a CED-4 homologue, were disrupted by ho-
mologous recombination. Stable clones of heterozygous (
 
2
 
/
 
1
 
) and homozygous (
 
2
 
/
 
2
 
)
Apaf-1 knockout ES cells that overexpressed Bcl-2 were generated. Withdrawal of serum
growth factors or stimulation of heterozygous ES cells with staurosporine (STS), ultraviolet
(UV)B irradiation, etoposide (VP16), or cisplatin induced apoptosis followed by cell death
(determined by failure to exclude propidium iodide dye). These cell death stimuli also induced
activation of several types of caspases and loss of mitochondrial membrane potential (
 
DC
 
) in
heterozygous (
 
1
 
/
 
2
 
) Apaf-1 knockout ES cells. In addition, overexpression of Bcl-2 protected
against these events in Apaf-1–expressing ES cells. In contrast, STS, UVB, and VP16 induced
little or no caspase activation and apoptosis in homozygous (
 
2
 
/
 
2
 
) Apaf-1 knockout ES cells.
Nevertheless, Apaf-1–deficient ES cells subjected to these cell death stimuli or deprived of
growth factors did eventually die through a nonapoptotic mechanism associated with loss of
 
DC
 
. Moreover, Bcl-2 overprotection preserved 
 
DC
 
, reduced the percentage of Apaf-1
 
2
 
/
 
2
 
 ES
cells undergoing cell death, and increased clonigenic survival. The extent of Bcl-2–mediated
 
cytoprotection was not significantly different for heterozygous (
 
2
 
/
 
1
 
) versus homozygous (
 
2
 
/
 
2
 
)
Apaf-1 knockout cells. Furthermore, although Bcl-2 could be readily coimmunoprecipitated
with Bax, associations with Apaf-1 were undetectable under conditions where Apaf-1 interac-
tions with procaspase-9 were observed. We conclude that Bcl-2 has cytoprotective functions
independent of Apaf-1, preserving mitochondrial function through a caspase-independent
mechanism.
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Introduction
 
Many of the mechanisms responsible for apoptosis and pro-
grammed cell death are conserved throughout the animal
kingdom (1). Members of the caspase family of cell death
protease are responsible for the phenomenon of apoptosis
in animal cells. When converted from their inactive zy-
mogen forms into active enzymes, these intracellular pro-
teases can cleave a variety of substrates that then produce
the characteristic morphological manifestations and associ-
ated biochemical changes commonly associated with this
form of cell demise.
Genetic analysis of developmental cell death in the nem-
 
atode, 
 
Caenorhabiditis elegans
 
, has revealed two essential cell
death genes, ced-3 and ced-4 (2). The ced-3 gene encodes
a caspase, which has several close homologues in humans
and other mammalian species (3). The CED-4 gene prod-
uct is required for CED-3 activation in 
 
C. elegans
 
. CED-4
is an ATP-binding protein that binds the pro-form of
CED-3 (4), forming an oligomeric complex that results in
proteolytic processing and activation of the CED-3 pro-
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tease (5). Apoptotic protease activating factor 1 (Apaf-1)
 
1
 
 is
a CED-4 homologue that is present in humans, mice, and
flies (6–11). Similar to CED-4, Apaf-1 binds certain pro-
caspases, forming ATP-dependent oligomeric complexes
that result in protease activation (12–15). Unlike CED-4,
however, Apaf-1 contains an additional domain that is not
found in the worm protein and that renders Apaf-1 depen-
dent on cytochrome c for its function as a caspase activator.
Because cytochrome c is normally found only in mito-
chondria, activation of Apaf-1 requires release of this pro-
tein from these organelles, thus coupling mitochondrial
damage to activation of caspases (for a review, see reference
16). Mice and flies with homozygous disruptions of their
Apaf-1 genes exhibit defects in developmental cell death in
some but not all tissues (7–11). Cells derived from Apaf-1
knockout mice display resistance to certain apoptotic stim-
uli which are thought to involve mitochondria through cy-
tochrome c release (7).
Bcl-2 family proteins represent an evolutionarily con-
served group of cell death regulators, with homologues
found in vertebrates and invertebrates. Members of this
family include both cell death–inducing and cell death–
blocking proteins (17). Though intensively investigated, it
remains unclear how Bcl-2 family proteins control cell life
and death. Many Bcl-2 family proteins contain a hydro-
phobic membrane-anchoring domain at their COOH ter-
minus that targets them to the membranes of mitochondria
and some other organelles (18, 19). Overexpression of
mammalian antiapoptotic proteins such as Bcl-2 or Bcl-X
 
L
 
has been shown to protect mitochondria from various cell
death stimuli, preserving transmembrane potential (
 
DC
 
)
and preventing release of cytochrome c and other apopto-
genic proteins (20, 21). Conversely, overexpression of
proapoptotic proteins such as Bax or Bak can result in re-
lease of cytochrome c from mitochondria and mitochon-
drial membrane depolarization (22–25).
In 
 
C. elegans
 
, the antiapoptotic Bcl-2 family member,
CED-9, suppresses apoptosis by binding CED-4, thereby
interfering with CED-4–dependent activation of pro–
CED-3 (26–28). The proapoptotic EGL-1 protein of this
nematode dimerizes with CED-9, releasing CED-4 and al-
lowing caspase activation (29). It has been proposed that
mammalian Bcl-2 homologues function similarly to their
counterparts in 
 
C. elegans
 
 (17). The antiapoptotic human
protein Bcl-X
 
L
 
, for example, reportedly associates with hu-
man Apaf-1 and suppresses apoptosis induced by overex-
pression of Apaf-1 (30–32). Overexpression of Bcl-2 also
may suppress caspase activation downstream of cytochrome
c in some circumstances (33, 34), consistent with the notion
that Bcl-2 can suppress Apaf-1. However, experiments us-
ing broad-spectrum caspase-inhibiting compounds have
provided evidence that several mammalian Bcl-2 family
proteins, including Bcl-2, Bcl-X
 
L
 
, Bax, and Bak, can regu-
late cytochrome c release and mitochondrial membrane po-
 
tential independently of caspases (22, 23, 35–37). More-
over, mammalian Bcl-2 family proteins can induce or
suppress caspase-independent nonapoptotic cell death (ne-
crosis) under some conditions (22, 38), arguing that they
operate via mechanisms other than by regulating caspase-acti-
vating proteins such as Apaf-1. To address the relation of
Apaf-1 to the cytoprotective mechanism by which mam-
malian Bcl-2 provides cytoprotection, we compared the ef-
fects of overexpressing Bcl-2 in murine that which con-
tained or lacked Apaf-1 because targeted ablation of the
 
apaf-1
 
 gene.
 
Materials and Methods
 
Plasmid Construction. 
 
cDNAs encoding Apaf-1 or its trun-
cated forms were obtained by PCR based on the published Apaf-1
DNA sequence (6). The full-length Apaf-1 cDNA was cloned
into pcI-neo (Promega) with a NH
 
2
 
-terminal Flag tag. Apaf-1
(Trp-Asp [
 
D
 
WD]) containing amino acids 1–420 was cloned into
pcDNA3-Myc to produce NH
 
2
 
-terminal–tagged Apaf-1 pro-
teins. Plasmids encoding human procaspase-9, procaspase-9
(Cys287Ala), human Bcl-X
 
L
 
, Bcl-2, Bax, and Bax (Iso-Gly-Asp-
Glu [
 
D
 
IGDE]) have been described (39, 40). Some of these were
subcloned into the EcoRI and XhoI sites of pcDNA3-myc to
produce NH
 
2
 
-terminal tagged proteins. A 0.9-kbp human Bcl-2
cDNA was subcloned into pPGK-neo bpA (gift of H. Baribault,
Deltagen, Inc., Menlo Park, CA) in place of neomycin cDNA.
pPGK-hygromycin has been described previously (41).
 
Cell Culture and Transfections.
 
293T cells were grown in
DMEM supplemented with 10% (vol/vol) FCS. 293T cells (3 
 
3
 
10
 
6
 
) seeded in 10-cm dishes were transiently transfected after 0.5 d
of culture with various plasmid DNAs using the SuperFect Trans-
fection reagent (Qiagen).
Apaf-1
 
1
 
/
 
2
 
Apaf-1
 
2
 
/
 
2
 
 ES cells have been described (7). ES cells
were grown in DMEM supplemented with leukemia inhibitory
factor, 15% FCS, 
 
l
 
-glutamine, and 
 
b
 
-mercaptoethanol. pPGK–
Bcl-2 and pPGK-hygromycin plasmid DNAs were linearized
with NotI or SalI and electroporated into ES cells (V/cm = 300;
capacitance = 960 
 
m
 
F). Stably transfected cells were obtained by
selection in media containing hygromycin (150 
 
m
 
g/ml) for 2 wk,
and clones were isolated using a micromanipulator. Subclones
expressing high levels of human Bcl-2 were identified by immu-
noblotting using an antihuman Bcl-2–specific antibody (42).
 
Immunoprecipitation and Immunoblot Analysis. 
 
293T cells were
transiently transfected with plasmids encoding Bcl-2, Myc–Apaf-1
(
 
D
 
WD), Flag–procaspase-9 (C287A), Myc-Bax, Myc-Bax
(
 
D
 
IGDE) mutant, or various combinations of these plasmids, nor-
malizing for total DNA content. After 2 d, cells were suspended
in lysis buffer (10 mM Hepes [pH 7.2], 142.5 mM KCl, 5 mM
MgCl
 
2
 
, 1 mM EGTA, 0.2% NP-40) containing a mixture of pro-
tease inhibitors (Boehringer). Lysates were precleared by incuba-
tion with protein G Sepharose 4B (Zymed Laboratories) without
antibody, and proteins were immunoprecipitated using anti-Myc
immobilized agarose gel (9E10) or IgG
 
1
 
 control (Santa Cruz Bio-
technology, Inc.), fractionated by SDS-PAGE, and then trans-
ferred onto nitrocellulose membranes and incubated with anti–
Bcl-2 rabbit serum or anti–Flag M2 antibody (Sigma-Aldrich).
Antibody detection was accomplished using an enhanced chemi-
luminescence method (Amersham Pharmacia Biotech). For direct
immunoblot analysis of ES cell lysates, 50 
 
m
 
g (total protein) of ly-
sate was prepared from exponentially growing ES cells and was
 
1
 
Abbreviations used in this paper:
 
 Apaf-1, apoptotic protease activating factor
1; CP, cisplatin; 
 
DC
 
, mitochondrial transmembrane potential; ES, em-
bryonic stem; PI, propidium iodide; STS, staurosporine. 
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separated in 12% SDS polyacrylamide gels, then blotted and ana-
lyzed using anti–Bcl-2 rabbit serum (42) or (as a control) anti–
 
a
 
-tubulin antibody (Sigma-Aldrich).
 
Assays for Apoptosis, Cell Death, and Clonigenic Survival.
 
For
experiments with ES cells, cell death and apoptosis, respectively,
were measured using one- or two-color FACS
 
®
 
-based methods
(7). In brief, 2 
 
3
 
 10
 
5
 
 ES cells per well were plated in 12-well
plates 1 d before replacement of medium with serum-free
DMEM, UV irradiation (Stratalinker 2400; Stratagene), or addi-
tion to cultures of etoposide (VP16), staurosporine (STS), or cis-
platinum (CP; Sigma-Aldrich). At various times thereafter, adher-
ent cells were recovered by trypsinization and pooled with
floating cells, then placed on ice in 0.2 ml of PBS containing 10
 
m
 
g/ml propidium iodide (PI), with or without 0.2 
 
m
 
g/ml of
FITC-conjugated annexin V (BD PharMingen). For determina-
tion of cell death, the percentage of cells which failed to exclude
PI dye was determined by flow cytometry (FACScan™; Becton
Dickinson). For apoptosis, the percentage of total recovered cells
that were annexin V positive but PI negative (apoptotic) was de-
termined.
Alternatively, cells were recovered from cultures (both floating
and adherent), fixed with 3.7% paraformaldehyde-PBS, and
stained with 0.1 
 
m
 
g/ml 4,6-diamino-2-phenylindole (DAPI
[40]). The percentage of cells with condensed chromatin and
fragmented nuclei was determined by UV microscopy. Each ex-
periment was performed in triplicate on several separate days. In
addition, the morphology of Apaf-1
 
1
 
/
 
2
 
 and Apaf-1
 
2
 
/
 
2
 
 ES cells
after treatment with apoptotic stimuli was determined by trans-
mission electron microscopy (42).
Release of lactate dehydrogenase (LDH) from dying cells was
measured using the medium recovered from cell cultures at vari-
ous times after withdrawing serum. In brief, to measure released
LDH, 0.1 ml aliquots of culture medium were mixed with 10 
 
m
 
l
10 mM NADH, 10 
 
m
 
l of 0.1 M Na-pyruvate (pH 7.4), and 0.88
ml 50 mM Na
 
2
 
HP0
 
4
 
 (pH 7.2). The rate of conversion of NADH
to NAD
 
1
 
 was determined by spectrophotometry, measuring the
decline in absorbance at OD 340 nm at 25
 
8
 
C. To determine cel-
lular LDH activity for normalization of data, cells were recovered
from cultures and resuspended in medium containing 0.1% Tri-
ton X-100, and LDH activity was measured. Cellular and released
LDH activity were then combined to determine total LDH activ-
ity in each cell culture. Data for released LDH were normalized
relative to total LDH and expressed as a percentage. All measure-
ments were performed in triplicate.
For clonigenic survival assays, ES cells were either treated with
STS or deprived of serum. For STS, 10
 
6
 
 ES cells were seeded in
6-cm dishes. The next day, 15 
 
m
 
M STS was added to cultures for
6 h. The cells were then washed, recovered by trypsinization, and
cultured in triplicate at 10
 
4
 
 cells per 35-mm dishes in fresh me-
dium lacking STS. Colony formation was meaured 6 d later by
crystal violet staining. Colony-forming efficiency was determined
by comparing the ratio of the numbers of colonies formed by
cells exposed to STS compared with untreated cells. For serum
deprivation, 10
 
5
 
 ES cells were seeded into 35-mm dishes in their
usual medium containing 15% fetal bovine serum. The next day,
the cells were washed three times with medium lacking serum,
and then cultured in serum-deficient medium for 9 d. The me-
dium was then replaced with serum-containing medium to allow
surviving cells to proliferate and form colonies, which were
scored 5 d later. Colony-forming efficiency was calculated as the
ratio of the number of colonies arising after serum deprivation
compared with the number of cells originally plated (10
 
5
 
).
 
Measurement of Mitochondrial Potential in ES Cells. 
 
To deter-
 
mine the percentage of ES cells experiencing loss of 
 
DC
 
, ES cells
were cultured as described above for apoptosis and cell death as-
says, and then both floating and adherent cells were recovered 1 d
after treatment with apoptosis inducers and incubated in DMEM
at 37
 
8
 
C with 40 nM 3,3
 
9
 
-dihexyloxacarbocyanine iodide
(DiOC
 
6
 
[3]) for 30 min, then analyzed by flow cytometry using
the FL1 channel. The percentages of cells with reduced fluores-
cence indicative of loss of 
 
DC
 
 were determined from duplicate
samples, and each experiment was repeated at least once.
 
Caspase Assays. 
 
ES cells were seeded at 3 
 
3
 
 10
 
6
 
 cells in 10-
cm diameter dishes and treated 1 d later with UV irradiation, an-
ticancer drugs, or serum deprivation as above. At 1 d after treat-
ment of ES cells with apoptosis inducers, cells were recovered
into lysis buffer (10 mM Tris-HCl [pH 7.3], 25 mM NaCl,
0.25% Triton X-100, 1 mM EDTA). After centrifugation at
16,000 
 
g
 
 for 30 min, the resulting supernatants were adjusted to 1
mg/ml with lysis buffer, and 25 
 
m
 
g total protein was incubated in
100 
 
m
 
l caspase buffer (50 mM Hepes [pH 7.2], 100 mM NaCl,
1 mM EDTA [pH 8.0], 10% sucrose, 0.1% 3[3-cholamidopropyl-
dimethylammonio]-1-propanesulfate [CHAPS], and 5 mM
dithiothreitol [DTT]) with 100 
 
m
 
M of various fluorigenic sub-
strate peptides, including acetyl-Asp-Glu-Val-Asp-(7-amino-4-
trifluoromethyl-coumarin) (Ac-DEVD-AFC), Ac-Tyr-Val-Ala-
Asp-AFC (Ac-YVAD-AFC), Ac-Leu-Glu-Val-Asp-AFC (Ac-
LEVD-AFC), Ac-Leu-Glu-His-Asp-AFC (Ac-LEHD-AFC),
benzyloxycarbonyl-Ile-Glu-Thr-Asp-AFC (z-IETD-AFC), and
z-Val-Asp-Val-Ala-Asp-AFC (z-VDVAD-AFC; Calbiochem).
Caspase activity was assayed using a fluorimeter plate reader
(Fmax™; Molecular Devices) in kinetic mode with excitation
and emission wavelengths at 405 and 519 nm, respectively, con-
tinuously measuring release of AFC (7-amino-4-trifluoromethyl-
coumarin) from substrate peptides as described (43). Data shown
represent AFC released after 30 min.
 
Results
 
Induction of Cell Death but Not Apoptosis in Apaf-1–deficient
ES Cells. 
 
To explore the relevance of Apaf-1 to the
mechanism by which Bcl-2 suppresses cell death, we used
ES cells in which one or both copies of the gene encoding
Apaf-1 were disrupted by homologous recombination (7),
thus providing a cellular context in which Apaf-1 was ei-
ther present or absent. First, the effects of several agents
that typically induce apoptosis was tested on Apaf-1
 
1
 
/
 
2
 
 and
Apaf-1
 
2
 
/
 
2
 
 ES cells. Apoptosis was monitored by micro-
scopic examination of fixed cells stained with the DNA-
binding fluorochrome DAPI, assessing the percentage of
cells that developed nuclear fragmentation and chromatin
condensation typical of apoptosis (40). Cell death was de-
termined by failure of cells to exclude the membrane-
impermeable dye, PI. In cultures of Apaf-1–expressing ES
cells, cytotoxic agents, including the protein kinase inhibi-
tor STS or DNA-damaging anticancer drugs such as etopo-
side (VP16) or CP (Fig. 1) induced marked increases in
both apoptosis (as manifested by nuclear fragmentation and
chromatin condensation observed with DAPI staining) and
cell death (as revealed by PI dye uptake). In contrast, little
or no increase in the percentage of apoptotic cells was in-
duced by these agents in cultures of Apaf-1–deficient ES
cells. Nevertheless, an significant increase in the percentage 
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of dead cells (i.e., cells failing to exclude PI dye) was ob-
served in cultures of Apaf-1
 
2/2 ES cells after exposure to
STS, VP16, and CP. Similar data were obtained when an
alternative vital dye was employed, namely trypan blue
(not shown). These observations were also confirmed using
an assay in which phosphatidylserine surface exposure is
detected by annexin V staining of cells, and plasma mem-
brane integrity is simultaneously assessed by PI dye exclusion
using two-color FACS® analysis (44). In Apaf-11/2 ES
cells, cytotoxic agents induced increases in the percentage
of both annexin V–positive/PI-negative (apoptotic) cells
and annexin-V–positive/PI-positive (nonapoptotic) cells.
In contradistinction, annexin V–positive cells were pre-
dominantly PI positive in cultures of Apaf-12/2 ES cells
treated with cytotoxic agents (data not presented), suggest-
ing a nonapoptotic demise.
Electron microscopic analysis of Apaf-1 2/2 ES cells after
exposure to apoptotic stimuli confirmed that these cells did
not undergo apoptosis, unlike the typical apoptotic features
seen in Apaf-11/2 cells, including chromatin condensation
with margination at the nuclear periphery, nuclear frag-
mentation, plasma membrane blebbing, and apoptotic body
formation (Fig. 2). Rather, Apaf-12/2 cells exposed to anti-
cancer drugs or treated with UV irradiation contained in-
tact nuclei with focal rather than peripheral chromatin con-
densation and had evidence of mitochondrial swelling and
distention of the endoplasmic reticulum and Golgi body.
Some of these cells had cytosolic vacuolarization, and occa-
sionally rupture of the plasma membrane was also evident.
We conclude therefore that Apaf-1–deficient cells treated
with anticancer drug or radiation die through a nonapop-
totic mechanism.
Overexpression of Bcl-2 in Apaf-11/2 and Apaf-12/2 ES
Cells.  Using a PGK promoter to drive expression of a
Bcl-2–encoding cDNA, stably transfected clones of het-
erozygous Apaf-11/2 and homozygous Apaf-12/2 ES cells
Figure 1. Induction of cell death but not apoptosis in Apaf-1–deficient ES cells. Apaf-11/2 and Apaf-12/2 ES cells were cultured in medium without
(control; CNTL) or with cytotoxic agents, including 10 mM STS, 100 mM VP16, or 50 mM CP. After 1–2 d, floating and attached cells were recovered
and pooled. Half were fixed and stained with DAPI, and half were placed on ice and then immediately analyzed for PI dye uptake using a flow cytome-
ter. (A and B, top) Representative photomicrographs are presented for fluorescence microscopy analysis of DAPI-stained cells, demonstrating nuclear
fragmentation and chromatin condensation typical of apoptosis in cultures of Apaf-11/2 ES cells treated with cytotoxic agents. In contrast, nuclei appear
mostly normal in cultures of Apaf-12/2 cells. (A and B, bottom) The percentage of cells with apoptotic nuclear morphology as revealed by DAPI-stain-
ing (hatched bars) and the percentage of dead cells as determined by PI dye uptake (black bars) were determined (mean 6 SD; n = 3).1713 Haraguchi et al.
that overexpressed Bcl-2 were generated. Fig. 3 shows re-
sults of an immunoblot analysis of lysates prepared from
two independent clones of Bcl-2–overexpressing Apaf-11/2
and Apaf-12/2 ES cells, making comparisons with clones of
control Apaf-11/2 and Apaf-12/2 ES cells that were elec-
troporated with a control plasmid and subjected to the
same hygromycin selection procedure. Note that the z26-
kD Bcl-2 protein is present at high levels in the expected
cell clones (arbitrarily called “A” and “B”) but not in the
hygromycin control clones of Apaf-11/2 and Apaf-12/2 ES
cells. Probing the same blot with an antibody to a-tubulin
confirmed loading of equivalent amounts of total protein
for each sample (Fig. 3).
From a total of 18 hygromycin-resistant Bcl-2–trans-
fected ES cells lacking Apaf-1, 8 expressed human Bcl-2,
whereas the other 10 failed to produce human Bcl-2 pro-
tein at levels that were detectable by immunoblotting.
From 24 clones of Bcl-2–transfected Apaf-11/2 ES cell
clones, 5 expressed Bcl-2. Though the experiments pre-
sented below focused on two of the Bcl-2–expressing
clones (A and B) each for Apaf-11/2 and Apaf-12/2 ES
cells, similar results were obtained with additional clones in
pilot experiments. Moreover, cell death experiments using
the ES cell clones that failed to express Bcl-2 at immu-
nodetectable levels produced results comparable to the
pPGK-hygromycin (control)-transfected ES cells (not
shown), consistent with the ineffective expression of the
pPGK–Bcl-2 plasmid in those particular stable transfectants.
Bcl-2 Overexpression Protects Apaf-1 Knockout Cells from
Death Induced by UV Irradiation and Anticancer Drugs.  To
explore the effect of Bcl-2 overexpression in an Apaf-1–
deficient cellular context, we contrasted the effects of vari-
ous cytotoxic stimuli on induction of cell death, as deter-
mined by PI dye uptake, in cultures of Apaf-11/2 and
Apaf-12/2 ES cells that had been transfected with either
hygromycin control or Bcl-2–expression plasmids. Fig. 4
presents the results of experiments in which Apaf-11/2 or
Apaf-12/2 ES cells were treated for 1–2 d with UV-irradi-
ation, the topoisomerase inhibitor etoposide (VP16), the
DNA-damaging drug CP, or the general kinase inhibitor,
STS. In all cases, cell death (failure to exclude PI) was in-
duced in cultures of both Apaf-11/2 and Apaf-12/2 ES
cells, although fewer percentages of the Apaf-1–deficient
cells died during the same time (Fig. 4 A). Overexpression
of Bcl-2 significantly reduced the percentage of cell death
induced by UV irradiation, VP16, CP (P , 0.05 by paired
t-test), and to some extent STS (P = 0.03–0.08, depending
on the particular clone examined) in both Apaf-11/2 and
Apaf-12/2 cells. Moreover, this protection afforded by Bcl-2
overexpression in both Apaf-11/2 (not shown) and Apaf-
12/2 (Fig. 4 B) ES cells was evident over a range of doses of
UV irradiation and concentrations of anticancer drugs.
Some quantitative differences in the extent of Bcl-2 cyto-
protection in Apaf-11/2 versus Apaf-12/2 cells were no-
ticeable, particularly with VP16, where the percentage in-
hibition of cell death by Bcl-2 was higher in Apaf-11/2
than in Apaf-12/2 cells (Fig. 4 A). However, the signifi-
cance of these observations should be interpreted with cau-
tion, given that the levels of Bcl-2 protein are not identical
in each of the stably transfected ES clones, and considering
Figure 2. Electron microscopic analysis of Apaf-11/2 and Apaf-12/2
ES cells. ES cells were treated without (A and C) or with (B and D) 60
mJ/cm2 UV irradiation, and were fixed 2 d later for electron microscopic
analysis. Representative transmission electron micrographs are presented,
showing (B) Apaf-11/2 cells with sequence of typical apoptotic features,
including plasma membrane blebbing and rupture and fragmented nu-
cleus with highly condensed chromatin (arrow), and (D) Apaf-12/2 cells
with intact nucleus containing slightly condensed chromatin, swollen mi-
tochondria, distention of endoplasmic reticulum and Golgi body, and cy-
tosolic vacuolarization. Some of the Apaf-12/2 cells with these morpho-
logical features also had evidence of plasma membrane rupture (arrow).
Figure 3. Immunoblot analysis of transfected ES cells. Stable transfec-
tants of Apaf-11/2 and Apaf-12/2 ES cells were prepared by electropora-
tion of the plasmid pPGK-hygromycin alone or in combination with
pPGK–Bcl-2, followed by selection in media containing 150 mg/ml hy-
gromycin for 2 wk. Independent cell clones were generated and analyzed
by SDS-PAGE (12% gel)/immunoblotting using lysates containing 50 mg
total protein (per lane) and antibodies specific for human Bcl-2 (top) or
a-tubulin (bottom). Data shown represent hygromycin control (Hygro)
Apaf-11/2 and Apaf-12/2 ES cells compared with two independent Bcl-
2–overexpressing clones, termed Bcl-2 (A) and Bcl-2 (B).1714 Bcl-2 Protects Cell Death by Caspase-independent Mechanism
that subtle differences may exist among clones in terms of
how they metabolize or efflux drugs.
Though Bcl-2 overexpression reduced cell death in-
duced by UV irradiation, VP16, and CP in both Apaf-11/2
and Apaf-12/2, it did not prevent cell cycle arrest, as deter-
mined by FACS®-based DNA content analysis (not
shown). UV irradiation, for example, induced predomi-
nantly G1 arrest, whereas VP16 and CP induced predomi-
nantly G2/M arrest. Among surviving cells, the percentages
of hygromycin control and Bcl-2–overexpressing cells in
Go/G1, S, or G2/M phases were not significantly different
(data not presented).
Bcl-2 Overexpression Prolongs Survival of Apaf-1–deficient
ES Cells in Absence of Growth Factors.  Gene transfer–medi-
ated overexpression of Bcl-2 has been reported to delay
or prevent cell death induced by withdrawal of growth fac-
tors from cultures of factor-dependent cells of various lin-
eages (for a review, see reference 45). We therefore asked
whether Bcl-2 overexpression in Apaf-11/2 and Apaf-12/2
ES cells could delay cell death induced by serum depriva-
tion. Gene transfer–mediated overexpression of Bcl-2 sup-
pressed cell death induced in cultures of Apaf-1–expressing
ES cells, as determined by PI dye exclusion assays (Fig. 5
A). Though death of Apaf-12/2 cells occurred with de-
layed kinetics relative to Apaf-11/2 ES cells, by 4 d after
withdrawal of growth factors, over half the Apaf-12/2 cells
failed to exclude PI dye (Fig. 5 A). Moreover, Bcl-2 over-
expression prolonged survival of both Apaf-11/2 and Apaf-
12/2 ES cells, as measured by PI exclusion.). Similar con-
clusions were reached when using release of LDH from
cells into culture medium as an indicator of cell death (Fig.
5 B) instead of PI dye exclusion. Cell cycle studies (i.e.,
DNA content analysis) indicated that growth factor–deprived
ES–hygromycin control and ES–Bcl-2 cells similarly ar-
rested in Go/G1 before dying, and excluded differences in
Figure 4. Bcl-2 inhibits death of Apaf-12/2
ES cells afer exposure to UV irradiation
and cytotoxic drugs. The Apaf-11/2 and
Apaf-12/2 ES cell transfectants were seeded
at 2 3 105 cells per well (2-cm) in 12-well
plates 1 d before UV irradiation (60–240
mJ/cm2) or addition of 100–300 mM VP16,
50–100 mM CP, or 2–15 mM STS. Floating
and adherent cells were recovered after 1 d,
and the percentage of dead cells that failed to
exclude PI was determined by flow cytome-
try (mean 6 SE; n = 3). (A) Comparison of
Apaf-11/2 and Apaf-12/2 ES cells treated
with 60 mJ/cm2 UV irradiation for 2 d or
with 100 mM VP16, 50 mM CP, or 15 mM
STS for 1 d. Cases where cell death was sig-
nificantly reduced in cultures of Bcl-2 (A)
and Bcl-2 (B) cells compared with hygro-
mycin control (Hygro) cells (p # 0.05 as de-
termined by unpaired t-test) are indicated by
*. (B) Effects of various doses of UV irradia-
tion or various concentrations of cytotoxic
drugs are compared for hygromycin control
(Hygro) and Bcl-2–overexpressing Apaf-1–
deficient ES cells. Data are representative of
multiple experiments.
cell proliferation as an explanation for the differences ob-
served in the relative numbers of surviving cells in cultures
deprived of serum growth factors (data not presented).
Bcl-2 Enhances Clonigenic Survival of Apaf-1–deficient ES
Cells.  To determine whether the Bcl-2-mediated differ-
ences in cell death rates measured in short-term cytotoxicity
assays correlate with long–term clonigenic survival, Bcl-
2–overexpressing or hygromycin control–transfected Apaf-
12/2 ES cells were either exposed to high-dose STS for 6 h
or deprived of serum for several days, then washed and
placed into complete medium to allow recovery and for-
mation of colonies of growing cells. As shown in Fig. 6,
Bcl-2 overexpression increased the clonigenic survival of
Apaf-1–deficient ES cells by approximately fivefold after
either exposure to STS or deprivation of serum.
Bcl-2 Protection in Absence of Caspase Activation. Apop-
tosis results from activation of caspases. A subgroup of these
proteases cleaves the tetrapeptide sequence DEVD (Asp-
Glu-Val-Asp [46]) and functions as the principal effectors
of apoptosis (caspases-3 and -7), whereas upstream, initiator
caspases have preferences for other tetrapeptide sequences,
such as IETD (Ile-Glu-Thr-Asp; caspases-8 and -10),
LEHD (Leu-Glu-His-Asp; caspase-9), LEVD (Leu-Glu-
Val-Asp; caspase-4), VDVAD (Val-Asp-Val-Ala-Asp; cas-
pase-2), and YVAD (Tyr-Val-Ala-Asp; caspase-1; references
47, 48). To explore whether caspase activation occurs in
Apaf-11/2 and Apaf-12/2 ES cells exposed to apoptogenic
stimuli, and to assess whether Bcl-2 overexpression pre-
vents activation of these caspases, we prepared lysates from
ES cells at various times after exposure to death stimuli and
assayed for active caspases using fluorigenic peptide sub-
strates. As shown in Fig. 7, growth factor withdrawal, UV-
irradiation, VP16, and CP all induced the activation of
DEVD-cleaving caspases in Apaf-1–containing ES cells.
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caspase activation, as expected (49, 50). In contrast, rela-
tively little DEVDase activity was observed in factor-deprived
and UV-treated ES cells that lacked Apaf-1, and no
caspase activity was detected in these cells after exposure to
anticancer drugs VP16 and CP (Fig. 7). Similar observa-
tions were made when examining the activities of various
initiator caspase activities using fluorigenic tetra- and pen-
tapeptide substrates VDVAD, LEVD, IETD, and LEHD.
For example, in lysates prepared from VP16-treated ES
cells, VDVAD-, LEVD-, IETD-, and LEHD-cleaving pro-
tease activity was present in Apaf-1–containing lysates de-
rived from Apaf-11/2 ES cells but was markedly reduced in
lysates from Bcl-2–overexpressing Apaf-11/2 cells (Fig. 7).
In contrast, none of these protease activities could be de-
tected in lysates prepared from Apaf-1–deficient ES cells.
Studies with the caspase-1 substrate, YVAD, demonstrated
no evidence of activation of this type of caspase in either
Apaf-11/2 or Apaf-12/2 ES cells (not shown). We con-
clude therefore that the cytoprotective effects of Bcl-2 in
Apaf-12/2 ES cells do not correlate with caspase activity,
suggesting a caspase-independent mechanism.
Bcl-2 Preserves DC in Apaf-12/2 ES Cells.  Loss of mi-
tochondrial membrane potential is a concomitant of apop-
tosis and cell death induced by many stimuli, occurring
either upstream or downstream of caspase activation, de-
pending on the particular stimulus employed (51, 52). To
explore further the mechanism by which Bcl-2 overex-
pression protects Apaf-1–deficient ES cells, the poten-
tial-sensitive dye 3,39-dihexyloxacarbocyanine iodide
DiOC6(3) was used to evaluate changes in DC after expo-
sure of Apaf-12/2 cells to UV irradiation, VP16, or STS.
As expected, loss of DC was induced in response to these
cell death stimuli in hygromycin control cells, as evidence
by a two- to threefold increase in the accumulation of cells
with reduced DiOC6(3) fluorescence (Fig. 8). In contrast,
significantly fewer cells suffered reductions in DC in cul-
tures of Bcl-2–transfected Apaf-12/2 ES cells (P , 0.05).
These results indicate that Bcl-2 can preserve mitochon-
drial function independently of Apaf-1.
Bcl-2 Binds Bax but Does Not Interact with Apaf-1.
Though Bcl-2 protected Apaf-1–deficient ES cells, indicat-
ing an Apaf-1–independent mechanism of action, we con-
sidered the possibility that Bcl-2 might be capable of oper-
ating through both Apaf-1–dependent and –independent
mechanisms. Since Bcl-2 homologues associate with Apaf-1
homologues in some lower organisms (e.g., CED-9 binds
CED-4 in C. elegans; for a review, see reference 53), we
addressed the question of whether Bcl-2 can associate with
Apaf-1 using a variety of experimental approaches, includ-
ing (i) yeast two-hybrid assays, (ii) in vitro protein-binding
assays using bacteria-produced glutathione S-transferase–
tagged proteins, and (iii) coimmunoprecipitation experi-
ments. Though only results from coimmunoprecipitation
experiments are presented here, similar conclusions were
reached with all three methods.
Figure 5. Bcl-2 prolongs survival of Apaf-11/2 and Apaf-12/2 ES cells
in the absence of growth factors. Stably transfected Apaf-11/2 hygromy-
cin control (Hygro), Bcl-2 (A), and Bcl-2 (B) cells (left) and Apaf-12/2
hygromycin control (Hygro), Bcl-2 (A), and Bcl-2 (B) cells (right) were
seeded at 105 cells per 2-cm well. After 12 h, cells attached to plates were
washed, and medium was replaced with DMEM lacking FCS. At various
times thereafter, (A) both adherent and floating cells were recovered and
analyzed by flow cytometry, determining the percentage of viable cells
capable of excluding PI (mean 6 SE; n = 3), or (B) LDH released into
the culture medium by dying cells was measured by enzyme assay (data
expressed as percentage relative to total LDH activity present in culture
supernatants and cell pellets; cells were lysed with 0.1% Triton X-100;
mean 6 SE; n = 3).
Figure 6. Bcl-2 enhances clonigenic survival of Apaf-12/2 ES cells.
Apaf-1–deficient ES cells were either (A) treated with 15 uM STS for 6 h,
or (B) deprived of serum for 9 d (2FCS). Cells were washed and cul-
tured for 5–6 d in complete medium containing serum. Cells were then
stained with crystal violet, and the number of colonies was counted
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Fig. 9 shows representative data from coimmunoprecipi-
tation experiments in which Bcl-2 and Apaf-1 were coex-
pressed at high levels by transient transfection in 293T cells.
For the experiments shown here, an Apaf-1 mutant lacking
the COOH-terminal domain containing multiple WD re-
peats, Apaf-1 (DWD), was employed because it accumu-
lated to much higher levels in transfected cells than full-
length Apaf-1, and because it retains the domains that
would be expected to bind Bcl-2 family proteins (30, 54);
however, similar conclusions were reached using the full-
length Apaf-1 protein (not shown). Although procaspase-9
Figure 7. Measurements of caspase activ-
ity in Apaf-11/2 and Apaf-12/2 ES cells.
The Apaf-11/2 transfectants hygromycin
(Hygro) and Bcl-2 (A) were compared with
the Apaf-12/2 ES cell transfectants hygro-
mycin (Hygro) and Bcl-2 (B) with regard to
caspase activation. To assay caspase activity,
3 3 106 ES cells were seeded in 10-cm
dishes 1 d before treatment. The cells were
left untreated or were treated with UV irra-
diation (240 mJ/cm2), VP16 (100 mM), or
CP (100 mM). Floating and adherent cells
were collected 24 h later, and lysates were
prepared. Alternatively, ES cells were
washed and cultured in serum-free medium
(2FCS) for 3 d. Caspase activity was mea-
sured using lysates containing 25 mg of total
cellular protein, monitoring release of AFC
from peptide substrates using continuous-
reading instruments. Enzyme activity is ex-
pressed as the rate of AFC fluorophore re-
leased (relative fluorescence units per minute per ng of total protein. (A) Ac-DEVD-AFC was used as the substrate. (B) Various substrate peptides were
compared using lysates from VP16-treated cells, including Z-VDVAD-AFC, Ac-LEVD-AFC, Z-IETD-AFC, and Ac-LEHD-AFC. Data are representa-
tive of a minimum of two experiments.
Figure 8. Bcl-2 preserves mitochondrial DC in Apaf-1–deficient ES
cells. Hygromycin control (Hygro)–transfected or Bcl-2–overexpressing
Apaf-12/2 ES cells (clones A and B) were cultured without further treat-
ment or were treated with UV irradiation (240 mJ/cm2), VP16 (100
mM), or STS (10 mM). After 24 h, floating and adherent cells were col-
lected and stained with 40 nM DiOC6(3), followed by FACS® analysis.
Loss of DC was visualized as a reduction in the fluorescence signal in the
FL1 channel. (A) Representative FACS® histograms are presented, show-
ing fluorescence intensity (log-scale, x-axis) versus relative cell number
(y-axis) for untreated (CNTL) and UV-irradiated hygromycin (Hygro)
control cells, Bcl-2 (A), and Bcl-2 (B) cells. (B) The percentages of cells
with reduced DiOC6(3) staining are shown (mean 6 SE; n = 2 or 3). Sta-
tistical significance was assessed by unpaired t-test. *P # 0.05.
Figure 9. Bcl-2 binds Bax but does not interact with Apaf-1. 293T
cells (3 3 106 cells per 10-cm dish) were transiently transfected with vari-
ous combinations of plasmids (denoted by 1 or 2), including 7 mg of
plasmid DNA encoding Bcl-2 in combination with 4 mg of plasmids
encoding either Myc-Bax (1), 8 mg Myc–Apaf-1 (DWD) (2), or 4 mg Myc-
Bax–DIGDE mutant (3). Alternatively, 293T cells were transiently trans-
fected with 7 mg of pFlag–CMV2–Caspase-9 (C287A) and 8 mg of Myc–
Apaf-1 (DWD)-producing plasmids (4). Cell extracts were prepared 2 d
later, and immunoprecipitates were prepared using anti-Myc antibody.
Immune complexes (IP) or cell lysates (100 mg total protein) were frac-
tionated by SDS-PAGE and then blotted to nitrocellulose filters, which
were incubated with anti–Bcl-2 or anti-Flag (M2) antibodies (top). Alter-
natively, cell lysates from the four transfections (1–4) were run directly in
gels (100 mg total protein) and analyzed by immunoblotting using anti-
Myc antibodies (lower two panels). Control IPs using mouse IgG1 instead
of anti-Myc failed to result in precipitation of any of the indicated pro-
teins (not shown), providing an additional specificity control. The posi-
tions of the Bcl-2, procaspase-9, Apaf-1 (DWD), Bax, and Bax (DIGDE)
protein are indicated by arrows.1717 Haraguchi et al.
was readily coimmunoprecipitated with myc epitope–
tagged Apaf-1 (DWD) protein, Bcl-2 was not (Fig. 9).
However, immunoblot analysis of lysates prepared from the
transiently transfected cells confirmed production of abun-
dant amounts of the Bcl-2 protein. Moreover, in side-by-
side comparisons, Bcl-2 protein was coimmunoprecipitated
from 293T cell lysates with Myc-tagged Bax but not with
Myc-tagged Apaf-1 (DWD), thus confirming that the Bcl-2
protein produced in these experiments was competent to
bind other proteins. Though Bcl-2 could be coimmuno-
precipitated with Myc-Bax, it did not bind a control Myc-
Bax (DIGDE) protein, which contains a deletion of four
amino acids required for Bcl-2 binding within the Bcl-2
homology (BH)3 domain of Bax (55). Similar results were
obtained when using Bcl-XL instead of Bcl-2 (not shown).
We conclude therefore that Bcl-2 and Bcl-XL do not bind
Apaf-1, at least not under the same conditions where Bcl-2
and Bcl-XL are competent to bind Bax and where Apaf-1 is
competent to bind procaspase-9. Bcl-2 and Bcl-xL also
failed to suppress apoptosis induced by transient overex-
pression of Apaf-1 (not shown).
Discussion
Alterations in the expression or function of Bcl-2 family
proteins have been associated with many human diseases,
including those characterized by excessive cell death
(stroke, heart failure, AIDS) and those involving cell accu-
mulation due to insufficient programmed cell death (can-
cer, autoimmunity [56]). Understanding the mechanisms of
action of Bcl-2 family proteins is therefore important for
devising approaches for eventually manipulating the func-
tions of these proteins for therapeutic benefit. In this re-
port, we have addressed the issue of whether the cytopro-
tective actions of Bcl-2 require the participation of the
CED-4 homologue, Apaf-1.
Using ES cells that lack Apaf-1 because of interruption
of both copies of their apaf-1 genes by homologous recom-
bination, we found that Bcl-2 retains cytoprotective activ-
ity even in the absence of Apaf-1. Specifically, Bcl-2 over-
expression reduced or delayed cell death induced by
growth factor deprivation, UV irradiation, and anticancer
drugs in Apaf-12/2 ES cells. Furthermore, the extent to
which Bcl-2 protected against cell death was similar in both
Apaf-1–expressing and Apaf-1–deficient ES cells. These
observations thus demonstrate unequivocally that Bcl-2
possesses Apaf-1–independent functions.
It has been debated whether Bcl-2 and its close relatives
such as Bcl-XL operate upstream of rather than at the level
of Apaf-1. On the one hand, Bcl-2 and Bcl-XL have been
shown to block release of cytochrome c from mitochondria
(20, 21, 36), which represents an event upstream of Apaf-1
activation. This ability of Bcl-2 and/or Bcl-XL appears to
be caspase independent, further arguing that Apaf-1 is not
involved, as the only known activity of Apaf-1 is as an acti-
vator of caspases. On the other hand, Bcl-2 overexpression
has been shown to block apoptosis downstream of cyto-
chrome c in some scenarios (33, 34). Also, Bcl-XL has been
reported to associate with Apaf-1 and to suppress apoptosis
induced by overexpression of Apaf-1, as well as to prevent
Apaf-1 interactions with procaspase-9 (30–32). However,
recent data raise suspicions about the ability of antiapop-
totic Bcl-2 family proteins to bind Apaf-1 (57), and in our
experiments, we were unable to demonstrate an association
of Bcl-2 or Bcl-XL with the Apaf-1 protein or fragments of
it. Moreover, in contrast to C. elegans CED-4 and CED-9,
where membrane-associated CED-9 has been demon-
strated to alter the intracellular location of CED-4, pulling
this protein to the same membrane locations where CED-9
resides (28), we have been unable to demonstrate an effect
of overexpression of Bcl-XL on the intracellular location of
Apaf-1 in either resting or apoptosis-stimulated cells (Hara-
guchi, M. and J.C. Reed, unpublished observations). Thus,
although we cannot exclude that an interaction of Bcl-2 or
Bcl-XL occurs with Apaf-1 under some unidentified condi-
tions, we have been unable to find any compelling evidence
to support this notion. By analogy to other well-known
suppressors (e.g., IkB-suppressing nuclear factor kB), if Bcl-2
or Bcl-XL were to function predominantly as Apaf-1 sup-
pressors, then one would expect Bcl-2 and/or Bcl-XL to
bind avidly to Apaf-1. This seems not to be the case.
Though Bcl-2 fails to physically or functionally interact
with Apaf-1, the CED-9/CED-4 paradigm for explaining
the mechanism of Bcl-2 family proteins may still apply. For
example, Bcl-2 could interact with other CED-4–like pro-
teins that have perhaps not yet been discovered in humans
or mammals. However, in this case, one would still expect
the cell death mechanism suppressed by Bcl-2 to involve
caspases, since CED-4 homologues operate as caspase acti-
vators. In this regard, we found that death of Apaf-12/2 ES
cells induced by some anticancer drugs proceeded via a
mechanism that resulted in no detectable activation of
caspase family proteases, and yet was Bcl-2 suppressible.
Moreover, the cell death seen in Apaf-12/2 ES cells did not
resemble apoptosis morphologically and was not suppress-
ible by a broad-spectrum caspase inhibitor (benzyloxycar-
bonyl-Val-Ala-Asp [zVAD] fluoromethyl ketone; Hara-
guchi, M. and J.C. Reed, unpublished observations).
Together, these observations argue against suppression of a
CED-4–like protein as the major mechanism by which
Bcl-2 opposes cell death.
Mitochondria have been shown to play an important
role in both apoptotic and nonapoptotic cell death (for a
review, see reference 51). Apaf-1 functions as a coupling
device that links mitochondria to the activation of caspases,
thereby ensuring an apoptotic demise of cells that have suf-
fered mitochondrial damage. However, if caspases are in-
hibited, mitochondrial damage can still trigger cell death
through nonapoptotic mechanisms. For example, loss of
cytochrome c from mitochondria can result not only in ap-
optosis due to Apaf-1–mediated caspase activation, but it
can also cause an arrest of electron transport within the re-
spiratory chain, resulting in generation of membrane-dam-
aging free radicals and cessation of mitochondrial ATP
production, culminating in necrosis (for a review, see ref-
erence 16). In this regard, we observed that Bcl-2–over-1718 Bcl-2 Protects Cell Death by Caspase-independent Mechanism
expressing Apaf-12/2 ES cells suffered loss of mitochondrial
membrane potential (DC) when exposed to UV irradiation
or anticancer drugs, and that Bcl-2 overexpression reduced
the percentage of Apaf-12/2 ES cells that lost DC. Bcl-2
also preserved mitochondrial oxidative function even in the
absence of Apaf-1, as determined by MTT dye reduction
assays (not shown). Thus, Apaf-1 is required neither for loss
of mitochondrial DC nor for cell death of ES cells when
exposed to UV irradiation or anticancer drugs. Further,
Bcl-2 preserves mitochondrial membrane potential via an
Apaf-1–independent mechanism, consistent with the idea
that Bcl-2 operates upstream of Apaf-1 at the level of the
mitochondria, where Bcl-2 predominantly localizes in cells
(42, 58).
If Bcl-2 controls a cell death checkpoint upstream of
Apaf-1, why then does loss of Apaf-1 gene function con-
tribute to neoplastic transformation in collaboration with
oncogenes in rodent cell transformation assays (59)? More-
over, why is programmed cell death in the developing ner-
vous system and some other locations dependent on Apaf-1
(7, 8)? One possibility is that extramitochondrial pathways
for activating Apaf-1 may exist, thus uncoupling mito-
chondria (the site of Bcl-2 action) from Apaf-1–mediated
activation of caspases. Another likely possibility is that
Apaf-1 participates in an amplification loop in which Apaf-
1–mediated activation of caspases converts what would
otherwise be sublethal injury into a lethal hit. In this re-
gard, caspases have been shown to trigger mitochondrial
permeability transition, resulting in loss of DC, mitochon-
drial swelling, rupture, and release of cytochrome c (60,
61). In vivo, circumstances may arise where physiological
cell death stimuli induce only a small subpopulation of mi-
tochondria in cells to dump cytochrome c, necessitating
that this small proportion of released cytochrome c acti-
vates Apaf-1 and secondarily triggers caspase-dependent
destruction of additional mitochondria, thereby commit-
ting the cell to death. Thus, although Bcl-2 may not di-
rectly regulate Apaf-1, functional interactions of Bcl-2 and
Apaf-1 are likely to occur within the context of these inter-
dependent cyclical relations involving mitochondria as
both initiators and targets in a cell death pathway. Future
genetic analysis of Apaf-1 deficiency in combination with
Bcl-2 and Bcl-XL gene knockouts in mice will undoubt-
edly contribute to a greater understanding of the interde-
pendence of Bcl-2 family proteins and Apaf-1 in vivo.
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